Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 646423, 7 pages
http://dx.doi.org/10.1155/2015/646423
Review Article

Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention

Department of Internal Medicine, The University of Tokyo Hospital, Tokyo 113-0033, Japan

Received 9 February 2015; Accepted 3 May 2015

Academic Editor: Tianxin Yang

Copyright © 2015 Shoko Horita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Evans, G. D. Barish, and Y. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar
  2. R. Eldor, R. A. DeFronzo, and M. Abdul-Ghani, “In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion,” Diabetes Care, vol. 36, no. 2, pp. S162–S174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” Nature Medicine, vol. 19, no. 5, pp. 557–566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Helsen and F. Claessens, “Looking at nuclear receptors from a new angle,” Molecular and Cellular Endocrinology, vol. 382, no. 1, pp. 97–106, 2014. View at Publisher · View at Google Scholar
  5. A. Elbrecht, Y. Chen, C. A. Cullinan et al., “Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2,” Biochemical and Biophysical Research Communications, vol. 224, no. 2, pp. 431–437, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. M. E. Greene, B. Blumberg, O. W. McBride et al., “isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping,” Gene Expression, vol. 4, no. 4-5, pp. 281–299, 1995. View at Google Scholar · View at Scopus
  7. A. J. Vidal-Puig, R. V. Considine, M. Jimenez-Liñan et al., “Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids,” The Journal of Clinical Investigation, vol. 99, no. 10, pp. 2416–2422, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Tontonoz, R. A. Graves, A. I. Budavari et al., “Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα,” Nucleic Acids Research, vol. 22, no. 25, pp. 5628–5634, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Medina-Gomez, S. L. Gray, L. Yetukuri et al., “PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism,” PLoS Genetics, vol. 3, no. 4, p. e64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar
  11. N. Kubota, Y. Terauchi, H. Miki et al., “PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Endo, M. Suzuki, H. Yamada et al., “Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling,” Cell Metabolism, vol. 13, no. 5, pp. 550–561, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Song, M. A. Knepper, X. Hu, J. G. Verbalis, and C. A. Ecelbarger, “Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats,” The Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 426–433, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Publisher · View at Google Scholar
  16. V. Vallon, E. Hummler, T. Rieg et al., “Thiazolidinedione-induced fluid retention is independent of collecting duct αENaC activity,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 721–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Borsting, V. P.-C. Cheng, C. K. Glass, V. Vallon, and R. Cunard, “Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney,” The American Journal of Physiology—Renal Physiology, vol. 302, no. 5, pp. F540–F551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Nofziger, L. Chen, M. A. Shane, C. D. Smith, K. K. Brown, and B. L. Blazer-Yost, “PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel,” Pflugers Archiv, vol. 451, no. 3, pp. 445–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Iwashima, M. Eto, S. Horiuchi, and H. Sano, “Advanced glycation end product-induced peroxisome proliferator-activated receptor γ gene expression in the cultured mesangial cells,” Biochemical and Biophysical Research Communications, vol. 264, no. 2, pp. 441–448, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Asano, M. Wakisaka, M. Yoshinari et al., “Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation,” Biochimica et Biophysica Acta, vol. 1497, no. 1, pp. 148–154, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Mudaliar, C. Pollock, M. G. Komala, S. Chadban, H. Wu, and U. Panchapakesan, “The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules,” American Journal of Physiology—Renal Physiology, vol. 305, no. 2, pp. F143–F154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology—Renal Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Google Scholar · View at Scopus
  23. J. Yang, Y. Zhou, and Y. Guan, “PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases,” Current Opinion in Nephrology and Hypertension, vol. 21, no. 1, pp. 97–105, 2012. View at Publisher · View at Google Scholar
  24. T. Kanjanabuch, L.-J. Ma, J. Chen et al., “PPAR-γ agonist protects podocytes from injury,” Kidney International, vol. 71, no. 12, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Rutkowski, Z. V. Wang, A. S. D. Park et al., “Adiponectin promotes functional recovery After podocyte ablation,” Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 268–282, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. G. J. Ko, Y. S. Kang, S. Y. Han et al., “Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats,” Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2750–2760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda, “Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells,” Diabetes, vol. 53, no. 1, pp. 200–208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Fujita, Y. Sugiyama, S. Taketomi et al., “Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a new antidiabetic agent,” Diabetes, vol. 32, no. 9, pp. 804–810, 1983. View at Publisher · View at Google Scholar · View at Scopus
  29. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Miyazaki and R. A. DeFronzo, “Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients,” Diabetes, Obesity and Metabolism, vol. 10, no. 12, pp. 1204–1211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Miyazaki, A. Mahankali, M. Matsuda et al., “Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone,” Diabetes Care, vol. 24, no. 4, pp. 710–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Gastaldelli, Y. Miyazaki, M. Pettiti et al., “The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 806–812, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. Defronzo, “From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus,” Diabetes, vol. 58, no. 4, pp. 773–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Gastaldelli, Y. Miyazaki, A. Mahankali et al., “The effect of pioglitazone on the liver: role of adiponectin,” Diabetes Care, vol. 29, no. 10, pp. 2275–2281, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. S. Banks, F. E. McAllister, J. P. Camporez et al., “An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ,” Nature, vol. 517, no. 7534, pp. 391–395, 2014. View at Publisher · View at Google Scholar
  38. K. J. McCarthy, R. E. Routh, W. Shaw, K. Walsh, T. C. Welbourne, and J. H. Johnson, “Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion,” Kidney International, vol. 58, no. 6, pp. 2341–2350, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Yoshimoto, M. Naruse, M. Nishikawa et al., “Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 272, no. 6, pp. E989–E996, 1997. View at Google Scholar · View at Scopus
  40. J. Weissgarten, S. Berman, S. Efrati, M. Rapoport, Z. Averbukh, and L. Feldman, “Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats,” Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1198–1204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Weigert, K. Brodbeck, A. Bierhaus, H. U. Häring, and E. D. Schleicher, “c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones,” Biochemical and Biophysical Research Communications, vol. 304, no. 2, pp. 301–307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Yoshioka, H. Nishino, T. Shiraki et al., “Antihypertensive effects of CS-045 treatment in obese Zucker rats,” Metabolism: Clinical and Experimental, vol. 42, no. 1, pp. 75–80, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. P. A. Sarafidis and G. L. Bakris, “Protection of the kidney by thiazolidinediones: an assessment from bench to bedside,” Kidney International, vol. 70, no. 7, pp. 1223–1233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Nakamura, C. Ushiyama, N. Shimada, K. Hayashi, I. Ebihara, and H. Koide, “Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients,” Journal of Diabetes and its Complications, vol. 14, no. 5, pp. 250–254, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Nakamura, C. Ushiyama, S. Osada, M. Hara, N. Shimada, and H. Koide, “Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria,” Metabolism: Clinical and Experimental, vol. 50, no. 10, pp. 1193–1196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. R. A. DeFronzo, D. Tripathy, D. C. Schwenke et al., “Pioglitazone for diabetes prevention in impaired glucose tolerance,” The New England Journal of Medicine, vol. 364, no. 12, pp. 1104–1115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Yanagawa, A. Araki, K. Sasamoto, S. Shirabe, and T. Yamanouchi, “Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes,” Metabolism, vol. 53, no. 3, pp. 353–357, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Aljabri, S. E. Kozak, and D. M. Thompson, “Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial,” American Journal of Medicine, vol. 116, no. 4, pp. 230–235, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPARγ agonists: time for a reassessment,” Trends in Endocrinology and Metabolism, vol. 23, no. 5, pp. 205–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. J. V. Huang, C. R. Greyson, and G. G. Schwartz, “PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty,” Journal of Lipid Research, vol. 53, no. 9, pp. 1738–1754, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Benbow, M. Stewart, and G. Yeoman, “Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure,” British Medical Journal, vol. 322, article 236, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Erdmann and R. G. Wilcox, “Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure,” European Heart Journal, vol. 29, no. 1, pp. 12–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. K. B. Sotiropoulos, A. Clermont, Y. Yasuda et al., “Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effects on edema and weight gain,” The FASEB Journal, vol. 20, no. 8, pp. 1203–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Kotake and N. Hirasawa, “Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes,” European Journal of Pharmacology, vol. 707, no. 1–3, pp. 95–103, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. A. D. Dede, S. Tournis, I. Dontas, and G. Trovas, “Type 2 diabetes mellitus and fracture risk,” Metabolism, vol. 63, no. 12, pp. 1480–1490, 2014. View at Publisher · View at Google Scholar
  56. A. Grey, M. Bolland, S. Fenwick et al., “The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial,” European Journal of Endocrinology, vol. 170, no. 2, pp. 255–262, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. J. P. Bilezikian, R. G. Josse, R. Eastell et al., “Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. 1519–1528, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Monami, I. Dicembrini, and E. Mannucci, “Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials,” Acta Diabetologica, vol. 51, no. 1, pp. 91–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. J. A. Dormandy, B. Charbonnel, D. J. A. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Diabetes Care, vol. 27, no. 1, pp. 256–263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Raskin, M. Rendell, M. C. Riddle, J. F. Dole, M. I. Freed, and J. Rosenstock, “A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes,” Diabetes Care, vol. 24, no. 7, pp. 1226–1232, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. P. A. Sarafidis, P. I. Georgianos, and A. N. Lasaridis, “PPAR-γ agonism for cardiovascular and renal protection,” Cardiovascular Therapeutics, vol. 29, no. 6, pp. 377–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, and A. M. Skene, “The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study,” Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1772–1780, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. R. M. Lago, P. P. Singh, and R. W. Nesto, “Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials,” The Lancet, vol. 370, no. 9593, pp. 1129–1136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Hong, A. Lockhart, B. Davis et al., “PPAR gamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells,” The FASEB Journal, vol. 17, no. 13, pp. 1966–1968, 2003. View at Google Scholar
  67. S. Muto, Y. Miyata, M. Imai, and Y. Asano, “Troglitazone stimulates basolateral rheogenic Na+/HCO-3 cotransport activity in rabbit proximal straight tubules,” Nephron Experimental Nephrology, vol. 9, no. 3, pp. 191–197, 2001. View at Publisher · View at Google Scholar
  68. A. Zanchi, A. Chiolero, M. Maillard, J. Nussberger, H.-R. Brunner, and M. Burnier, “Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 3, pp. 1140–1145, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. J. M. Gonzalez-Campoy, J. C. Romero, and F. G. Knox, “Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems,” Kidney International, vol. 35, no. 3, pp. 767–777, 1989. View at Publisher · View at Google Scholar · View at Scopus
  70. S. C. Kiley and R. L. Chevalier, “Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF,” The American Journal of Physiology—Renal Physiology, vol. 293, no. 3, pp. F895–F903, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Burgermeister and R. Seger, “PPARγ and MEK interactions in cancer,” PPAR Research, vol. 2008, Article ID 309469, 16 pages, 2008. View at Publisher · View at Google Scholar
  72. S. Kousteni, T. Bellido, L. I. Plotkin et al., “Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity,” Cell, vol. 104, no. 5, pp. 719–730, 2001. View at Google Scholar · View at Scopus
  73. Y. Li, H. Yamada, Y. Kita et al., “Roles of ERK and cPLA2 in the angiotensin II-mediated biphasic regulation of Na+-HCO3 transport,” Journal of the American Society of Nephrology, vol. 19, no. 2, pp. 252–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. D.-H. Lee, D.-B. Park, Y.-K. Lee et al., “The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats,” Metabolism: Clinical and Experimental, vol. 54, no. 10, pp. 1282–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Zhou, G. Liu, Z. Jia et al., “Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters,” American Journal of Physiology—Renal Physiology, vol. 305, no. 10, pp. F1491–F1497, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Edemir, H. Pavenstädt, E. Schlatter, and T. Weide, “Mechanisms of cell polarity and aquaporin sorting in the nephron,” Pflügers Archiv European Journal of Physiology, vol. 461, no. 6, pp. 607–621, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. M. L. A. Kortenoeven and R. A. Fenton, “Renal aquaporins and water balance disorders,” Biochimica et Biophysica Acta—General Subjects, vol. 1840, no. 5, pp. 1533–1549, 2014. View at Publisher · View at Google Scholar
  78. J. L. Wilson, C. A. Miranda, and M. A. Knepper, “Vasopressin and the regulation of aquaporin-2,” Clinical and Experimental Nephrology, vol. 17, no. 6, pp. 751–764, 2013. View at Publisher · View at Google Scholar
  79. T. Ma, Y. Song, B. Yang et al., “Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 4386–4391, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Castrop and I. M. Schiessl, “Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2),” The American Journal of Physiology: Renal Physiology, vol. 307, no. 9, pp. F991–F1002, 2014. View at Publisher · View at Google Scholar
  81. N. Markadieu and E. Delpire, “Physiology and pathophysiology of SLC12A1/2 transporters,” Pflugers Archiv European Journal of Physiology, vol. 466, no. 1, pp. 91–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Fu, M. Gerasimova, F. Batz et al., “PPARγ agonist-induced fluid retention depends on aENaC expression in connecting tubules,” Nephron, vol. 129, no. 1, pp. 68–74, 2015. View at Publisher · View at Google Scholar
  83. H. S. Chou, K. E. Truitt, J. B. Moberly et al., “A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus,” Diabetes, Obesity and Metabolism, vol. 14, no. 11, pp. 1000–1009, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. A. M. DePaoli, L. S. Higgins, R. R. Henry, C. Mantzoros, F. L. Dunn, and INT131-007 Study Group, “Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?” Diabetes Care, vol. 37, no. 7, pp. 1918–1923, 2014. View at Publisher · View at Google Scholar